Register Login

XENON PHARMACEUTICALS INC. (XENE)

SymbolXENE
NameXENON PHARMACEUTICALS INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address200-3650 GILMORE WAY, BURNABY, British Columbia, V5G 4W8, Canada
Telephone+1 604 484-3300
Fax—
Email—
Websitehttps://www.xenon-pharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001582313
Description

Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets.

Additional info from NASDAQ:
Founded in 1984, Xilinx is the leader in FPGAs by market share. Its chips are critical in the performance of various devices in the communications, data processing, industrial, consumer, and automotive markets.

2026-08-28 20:25

📋 CHRISTOPHER KENNEY (Officer) plans to sell 7K shares of XENON PHARMACEUTICALS INC (at $61.93 each, total $438K) Filed: Aug 28, 2026 | ID: 008816

Read more
2026-08-28 20:01

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-26 20:01

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Read more
2026-08-07 12:05

New Form SCHEDULE 13G/A - Xenon Pharmaceuticals Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000315066-26-002245 <b>Size:</b> 11 KB

Read more
2026-08-06 20:01

Xenon Reports Q2 2026 Financial Results and Provides Business Update

Read more
2026-07-31 20:01

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-07-30 20:01

Xenon to Report Q2 2026 Financial Results on August 6, 2026

Read more
2026-07-02 20:01

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-09 01:19

PATOU GARY 🔴 sold 1.3K shares of Xenon Pharmaceuticals Inc. (XENE) at $53.14 Transaction Date: Jun 05, 2026 | Filing ID: 262672

Read more
2026-06-09 01:19

Cannon Gillian 🔴 sold 1.2K shares of Xenon Pharmaceuticals Inc. (XENE) at $53.14 Transaction Date: Jun 05, 2026 | Filing ID: 262671

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07217860 An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) Phase3 Bipolar Depression Enrolling_By_Invitation 2025-10-30 2029-08-01 ClinicalTrials.gov
NCT07172516 A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associa… Phase3 Bipolar Disorder Recruiting 2025-08-08 2028-08-01 ClinicalTrials.gov
NCT07076407 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (… Phase3 Major Depressive Disorder Recruiting 2025-07-08 2027-07-01 ClinicalTrials.gov
NCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder Phase3 Major Depressive Disorder Enrolling_By_Invitation 2025-03-18 2027-03-01 ClinicalTrials.gov
NCT06775379 A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Phase3 Major Depressive Disorder Recruiting 2024-12-20 2026-10-01 ClinicalTrials.gov
NCT05716100 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Phase3 Focal Onset Seizures Recruiting 2023-05-09 2026-12-01 ClinicalTrials.gov
NCT05718817 An Open-label Study of XEN1101 in Epilepsy Phase3 Focal Epilepsy Enrolling_By_Invitation 2023-04-25 2033-06-01 ClinicalTrials.gov
NCT05667142 A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-… Phase3 Primary Generalized Tonic-Clonic Seizures Recruiting 2023-02-14 2027-06-01 ClinicalTrials.gov
NCT05614063 A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Phase3 Focal Onset Seizures Completed 2022-11-18 2026-02-03 ClinicalTrials.gov
NCT05376150 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major D… Phase2 Major Depressive Disorder Completed 2022-05-19 2023-10-16 ClinicalTrials.gov
NCT04912856 An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-… Phase3 Epilepsy Terminated 2021-08-17 2023-11-17 ClinicalTrials.gov
NCT04952467 Single-dose Mass Balance Recovery and Metabolite Profile and Identification of … Phase1 Healthy Volunteers Completed 2021-07-14 2021-10-04 ClinicalTrials.gov
NCT04639310 XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalo… Phase3 Epilepsy Terminated 2021-03-29 2023-05-16 ClinicalTrials.gov
NCT03796962 A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Phase2 Focal Epilepsy Active_Not_Recruiting 2019-01-30 2028-10-01 ClinicalTrials.gov
NCT03467100 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Ora… Phase1 Healthy Volunteers Completed 2018-02-19 2018-12-19 ClinicalTrials.gov
NCT03468725 Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Sti… Phase1 Healthy Male Volunteers Completed 2018-02-13 2018-07-31 ClinicalTrials.gov
NCT03340220 Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascendin… Phase1 Healthy Volunteers Completed 2017-11-13 2021-11-26 ClinicalTrials.gov
NCT02656043 A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel Phase1 Acne Vulgaris Completed 2015-09-17 2017-03-17 ClinicalTrials.gov
NCT01486446 Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and … Phase1 Primary Erythromelalgia Completed 2011-12-01 2012-05-01 ClinicalTrials.gov
NCT01195636 A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 … Phase2 Postherpetic Neuralgia Completed 2010-08-01 2011-03-01 ClinicalTrials.gov
NCT01090622 Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgi… Phase1 Primary Erythromelalgia Completed 2010-04-01 2010-09-01 ClinicalTrials.gov
NCT00954356 Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extra… Phase2 Dental Pain Completed 2009-09-01 2009-12-01 ClinicalTrials.gov
NCT00813670 Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers Phase1 Healthy Human Volunteers Completed 2008-11-01 2009-07-01 ClinicalTrials.gov
Total clinical trials: 23
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06775379
Azetukalner Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06775379
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Azetukalner Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Azetukalner Other Phase PHASE3 Major Depressive Disorder ENROLLING_BY_INVITATION NCT06922110
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Azetukalner Other Phase PHASE3 Bipolar Depression ENROLLING_BY_INVITATION NCT07217860
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Azetukalner Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Azetukalner Other Phase PHASE3 Major Depressive Disorder ENROLLING_BY_INVITATION NCT06922110
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Placebo Other Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01486446
XPF-002 Other Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01486446
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Placebo Other Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01090622
XPF-001 Other Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01090622
Placebo Other Phase PHASE2 Postherpetic Neuralgia COMPLETED NCT01195636
XPF-002 Other Phase PHASE2 Postherpetic Neuralgia COMPLETED NCT01195636
Microcrystalline Cellulose Other Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03468725
XPF-008 Other Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03468725
Placebo Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02656043
XPF-005 Other Phase PHASE1 Acne Vulgaris COMPLETED NCT02656043
Inert Ingredients Oral Product Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03467100
XEN901 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03467100
14C-XEN1101 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04952467
Itraconazole 400mg Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
XPF-010 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
Microcrystalline Cellulose Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
XPF-008 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
Placebo Other Phase PHASE3 Epilepsy TERMINATED NCT04639310
XEN496 Other Phase PHASE3 Epilepsy TERMINATED NCT04639310
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05376150
XEN1101 20 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05376150
XEN1101 10 mg Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05376150
XEN1101 Other Phase PHASE2 Focal Epilepsy ACTIVE_NOT_RECRUITING NCT03796962
XEN496 Other Phase PHASE3 Epilepsy TERMINATED NCT04912856
Placebo Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
XEN1101 Other Phase PHASE3 Focal Onset Seizures COMPLETED NCT05614063
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Azetukalner Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06775379
Azetukalner Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06775379
Azetukalner Other Phase PHASE3 Major Depressive Disorder ENROLLING_BY_INVITATION NCT06922110
Placebo Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
XEN1101 Other Phase PHASE3 Focal Onset Seizures RECRUITING NCT05716100
Placebo Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
XEN1101 Other Phase PHASE3 Primary Generalized Tonic-Clonic Seizures RECRUITING NCT05667142
Placebo Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Disorder RECRUITING NCT07172516
Azetukalner Other Phase PHASE3 Bipolar Depression ENROLLING_BY_INVITATION NCT07217860
XEN1101 Other Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
High Dose Asenapine maleate transdermal patch DRUG Phase PHASE3 Schizophrenia COMPLETED NCT02876900
Low Dose Asenapine maleate transdermal patch DRUG Phase PHASE3 Schizophrenia COMPLETED NCT02876900
HP-1050 Patch DRUG Phase PHASE1 Cumulative Irritation and Sensitization UNKNOWN NCT04624867
Diclofenac Sodium Active Topical Patch 2 DRUG Phase PHASE2 Osteoarthritis of the Knee COMPLETED NCT03277066
Diclofenac Sodium Active Topical Patch 1 DRUG Phase PHASE2 Osteoarthritis of the Knee COMPLETED NCT03277066
Saline Patch DRUG Phase PHASE1 Osteoarthritis of the Knee COMPLETED NCT04882319
HP-5000 Placebo Patch DRUG Phase PHASE1 Osteoarthritis of the Knee COMPLETED NCT04882319
HP-5000 Topical Patch DRUG Phase PHASE1 Osteoarthritis of the Knee COMPLETED NCT04882319
d-Amphetamine Transdermal Patch DRUG Phase PHASE2 Attention Deficit Hyperactivity Disorder COMPLETED NCT01711021
Placebo patch DRUG Phase PHASE2 Osteoarthritis of the Knee COMPLETED NCT03277066
Diclofenac sodium active topical patch DRUG Phase PHASE3 Osteoarthritis Pain of the Knee COMPLETED NCT04683627
Oral Ondansetron DRUG Phase PHASE1 Postoperative Nausea and Vomiting COMPLETED NCT07498751
IV Ondansetron DRUG Phase PHASE1 Postoperative Nausea and Vomiting COMPLETED NCT07498751
Matching Placebo of LPI-1503 DRUG Phase PHASE1 Postoperative Nausea and Vomiting COMPLETED NCT07498751
LPI-1503 DRUG Phase PHASE1 Postoperative Nausea and Vomiting COMPLETED NCT07498751
Azetukalner DRUG Phase PHASE3 Major Depressive Disorder RECRUITING NCT07076407
XEN1101 20 mg DRUG Phase PHASE2 Major Depressive Disorder COMPLETED NCT05376150
XEN1101 10 mg DRUG Phase PHASE2 Major Depressive Disorder COMPLETED NCT05376150
14C-XEN1101 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04952467
XEN496 DRUG Phase PHASE3 Epilepsy TERMINATED NCT04912856
XEN1101 DRUG Phase PHASE3 Focal Epilepsy ENROLLING_BY_INVITATION NCT05718817
Inert Ingredients Oral Product DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03467100
XEN901 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03467100
Itraconazole 400mg DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
XPF-010 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03340220
Microcrystalline Cellulose DRUG Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03468725
XPF-008 DRUG Phase PHASE1 Healthy Male Volunteers COMPLETED NCT03468725
XPF-005 DRUG Phase PHASE1 Acne Vulgaris COMPLETED NCT02656043
XPF-002 DRUG Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01486446
Placebo DRUG Phase PHASE3 Schizophrenia COMPLETED NCT02876900
placebo DRUG Phase PHASE2 Dental Pain COMPLETED NCT00954356
XPF-001 DRUG Phase PHASE1 Primary Erythromelalgia COMPLETED NCT01090622
Total products: 180